Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Cryo-Cell International, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

OLDSMAR, FLA.--(BUSINESS WIRE)--CRYO-CELL INTERNATIONAL, INC. (NYSE AMERICAN LLC: CCEL) (THE COMPANY, CRYO-CELL), THE WORLD'S FIRST PRIVATE CORD BLOOD BANK TO SEPARATE AND STORE STEM CELLS IN 1992, ANNOUNCED THAT THE COMPANY WILL NOT DECLARE A QUARTERLY CASH DIVIDEND FOR THE THIRD QUARTER OF FISCAL 2025. THIS DECISION REFLECTS LOWER-THAN-EXPECTED PROFITABILITY. CRYO-CELL MAY OR MAY NOT REINSTATE A DIVIDEND IN FUTURE PERIODS, AND ANY FUTURE DECISIONS REGARDING DIVIDEND DECLARATIONS WILL BE B.

CRYO-CELL INTERNATIONAL, INC. PROVIDES DIVIDEND UPDATE

OLDSMAR, FLA.--(BUSINESS WIRE)--CRYO-CELL INTERNATIONAL, INC. (NYSE AMERICAN LLC: CCEL) (THE COMPANY), THE WORLD'S FIRST PRIVATE CORD BLOOD BANK TO SEPARATE AND STORE STEM CELLS IN 1992, ANNOUNCED RESULTS FOR THE FISCAL SECOND QUARTER ENDED MAY 31, 2025. FINANCIAL RESULTS REVENUE THE REVENUES FOR THE SECOND QUARTER OF FISCAL 2025 WERE $7.9 MILLION COMPARED TO $8.0 MILLION FOR THE SECOND QUARTER OF FISCAL 2024, A 1% DECREASE. THE REVENUES FOR THE SECOND QUARTER OF FISCAL 2025 CONSISTED OF $7.8.

CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2025 FINANCIAL RESULTS

OLDSMAR, FLA.--(BUSINESS WIRE)--CRYO-CELL INTERNATIONAL, INC. (NYSE AMERICAN LLC SYMBOL: CCEL) (CRYO-CELL), THE WORLD'S FIRST PRIVATE CORD BLOOD BANK TO SEPARATE AND STORE STEM CELLS IN 1992, ANNOUNCED TODAY THAT, AS A RESULT OF THE CURRENT ECONOMIC ENVIRONMENT AND OTHER CAPITAL ALLOCATION ALTERNATIVES, ITS BOARD OF DIRECTORS HAS APPROVED THE PAYMENT OF A REDUCED, QUARTERLY CASH DIVIDEND OF $0.15 PER SHARE OF COMMON STOCK TO BE PAID TO ITS SHAREHOLDERS OF RECORD AS OF THE CLOSE OF BUSINESS ON.

CORD BLOOD BANKING LEADER CRYO-CELL ANNOUNCES CASH DIVIDEND

OLDSMAR, FLA.--(BUSINESS WIRE)--CRYO-CELL INTERNATIONAL, INC. (NYSE AMERICAN LLC: CCEL) (THE COMPANY), THE WORLD'S FIRST PRIVATE CORD BLOOD BANK TO SEPARATE AND STORE STEM CELLS IN 1992, ANNOUNCED RESULTS FOR ITS FISCAL YEAR ENDED NOVEMBER 30, 2024. FINANCIAL RESULTS REVENUE CONSOLIDATED REVENUES FOR FISCAL 2024 WERE $32.0 MILLION COMPARED TO $31.3 MILLION FOR FISCAL 2023. THE REVENUES FOR FISCAL 2024 CONSISTED OF $31.6 MILLION IN PROCESSING AND STORAGE FEE REVENUE, $68,000 IN PRODUCT REVENUE.

CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2024

OLDSMAR, FLA.--(BUSINESS WIRE)--CRYO-CELL INTERNATIONAL, INC. (NYSE AMERICAN LLC SYMBOL: CCEL) (CRYO-CELL), THE WORLD'S FIRST PRIVATE CORD BLOOD BANK TO SEPARATE AND STORE STEM CELLS IN 1992, ANNOUNCED TODAY THAT ITS BOARD OF DIRECTORS HAS APPROVED THE PAYMENT OF A QUARTERLY CASH DIVIDEND OF $0.25 PER SHARE OF COMMON STOCK TO BE PAID TO ITS SHAREHOLDERS OF RECORD AS OF THE CLOSE OF BUSINESS ON FEBRUARY 14, 2025. THE DIVIDEND IS EXPECTED TO BE PAID ON FEBRUARY 28, 2025. THE BOARD OF DIRECTORS.

CORD BLOOD BANKING LEADER CRYO-CELL ANNOUNCES REGULAR QUARTERLY CASH DIVIDEND AND PAUSE OF STRATEGIC INITIATIVES

OLDSMAR, FLA.--(BUSINESS WIRE)--CRYO-CELL INTERNATIONAL, INC. (NYSE AMERICAN LLC SYMBOL: CCEL) (THE COMPANY), THE WORLD'S FIRST PRIVATE CORD BLOOD BANK TO SEPARATE AND STORE STEM CELLS IN 1992, ANNOUNCED RESULTS FOR THE FISCAL THIRD QUARTER ENDED AUGUST 31, 2024. FINANCIAL RESULTS REVENUE CONSOLIDATED REVENUES FOR THE THIRD QUARTER OF FISCAL 2024 WERE $8.07 MILLION COMPARED TO $7.87 MILLION FOR THE THIRD QUARTER OF FISCAL 2023. NET INCOME THE COMPANY REPORTED NET INCOME FOR THE THREE MONTHS E.

CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD QUARTER 2024 FINANCIAL RESULTS

OLDSMAR, FLA.--(BUSINESS WIRE)--CRYO-CELL INTERNATIONAL, INC. (NYSE AMERICAN LLC: CCEL ) (THE COMPANY), THE WORLD'S FIRST PRIVATE CORD BLOOD BANK TO SEPARATE AND STORE STEM CELLS IN 1992, ANNOUNCED RESULTS FOR THE FISCAL FIRST QUARTER ENDED FEBRUARY 29, 2024. FINANCIAL RESULTS REVENUE THE REVENUES FOR THE FIRST QUARTER OF FISCAL 2024 WERE $7.85 MILLION COMPARED TO $7.82 MILLION FOR THE FIRST QUARTER OF FISCAL 2023. THE REVENUES FOR THE FIRST QUARTER OF FISCAL 2024 CONSISTED OF $7.81 MILLION I.

CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2024 FINANCIAL RESULTS

OLDSMAR, FLA.--(BUSINESS WIRE)--CRYO-CELL INTERNATIONAL, INC. (NYSE AMERICAN LLC SYMBOL: CCEL) (THE COMPANY), THE WORLD'S FIRST PRIVATE CORD BLOOD BANK TO SEPARATE AND STORE STEM CELLS IN 1992, ANNOUNCED RESULTS FOR THE FISCAL THIRD QUARTER ENDED AUGUST 31, 2023. FINANCIAL RESULTS REVENUE CONSOLIDATED REVENUES FOR THE THIRD QUARTER OF FISCAL 2023 WERE $7.87 MILLION COMPARED TO $7.68 MILLION FOR THE THIRD QUARTER OF FISCAL 2022. THE REVENUES FOR THE THIRD QUARTER OF FISCAL 2023 CONSISTED OF $7.

CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD QUARTER 2023 FINANCIAL RESULTS

OLDSMAR, FLA.--(BUSINESS WIRE)--CRYO-CELL INTERNATIONAL, INC. (NYSE AMERICAN LLC: CCEL) (THE COMPANY), THE WORLD'S FIRST PRIVATE CORD BLOOD BANK TO SEPARATE AND STORE STEM CELLS IN 1992, ANNOUNCED RESULTS FOR THE FISCAL SECOND QUARTER ENDED MAY 31, 2023. FINANCIAL RESULTS REVENUE CONSOLIDATED REVENUES FOR THE SECOND QUARTER OF FISCAL 2023 WERE $7.77 MILLION COMPARED TO $7.63 MILLION FOR THE SECOND QUARTER OF FISCAL 2022, A 2% INCREASE. THE REVENUES FOR THE SECOND QUARTER OF FISCAL 2023 CONSIS.

CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2023 FINANCIAL RESULTS

OLDSMAR, FLA.--(BUSINESS WIRE)--CRYO-CELL INTERNATIONAL, INC. (NYSE AMERICAN LLC: CCEL ) (THE COMPANY), THE WORLDS FIRST PRIVATE CORD BLOOD BANK TO SEPARATE AND STORE STEM CELLS IN 1992, ANNOUNCED RESULTS FOR THE FISCAL FIRST QUARTER ENDED FEBRUARY 28, 2023. FINANCIAL RESULTS REVENUE THE REVENUES FOR THE FIRST QUARTER OF FISCAL 2023 WERE $7.82 MILLION COMPARED TO $7.26 MILLION FOR THE FIRST QUARTER OF FISCAL 2022. THE REVENUES FOR THE FIRST QUARTER OF FISCAL 2023 CONSISTED OF $7.56 MILLION IN PROCESSING AND STORAGE FEE REVENUE, $32,000 IN PRODUCT REVENUE AND APPROXIMATELY $231,000 IN PUBLIC BANKING REVENUE COMPARED TO $7.16 MILLION IN PROCESSING AND STORAGE FEES, APPROXIMATELY $18,000 IN PRODUCT REVENUE AND APPROXIMATELY $83,000 IN PUBLIC BANKING REVENUE FOR THE FIRST QUARTER OF FISCAL 2022. NET INCOME THE COMPANY REPORTED NET INCOME OF APPROXIMATELY $767,000 OR $0.09 PER BASIC AND DILUTED COMMON SHARE FOR THE THREE MONTHS ENDED FEBRUARY 28, 2023 COMPARED TO NET INCOME OF APPROXIMATELY $832,000, OR $0.10 PER BASIC AND DILUTED COMMON SHARE FOR THE SAME PERIOD IN 2022. NET INCOME FOR THE THREE MONTHS ENDED FEBRUARY 28, 2023 RESULTED FROM AN 8% INCREASE IN REVENUE, A 2% DECREASE IN COST OF SALES AND A 15% INCREASE IN SELLING, GENERAL AND ADMINISTRATIVE EXPENSES. ALSO, FOR THE THREE MONTHS ENDED FEBRUARY 28, 2023, THE COMPANY RECORDED A DECREASE OF APPROXIMATELY $165,000 TO THE FAIR VALUE OF THE CONTINGENT CONSIDERATION COMPARED TO A DECREASE OF APPROXIMATELY $116,000 TO THE FAIR VALUE OF THE CONTINGENT CONSIDERATION FOR THE THREE MONTHS ENDED FEBRUARY 28, 2022. THE CONTINGENT CONSIDERATION IS THE CURRENT VALUATION OF THE POTENTIAL EARNOUT THAT CORD:USE CORD BLOOD BANK, INC. IS ENTITLED TO FROM THE COMPANYS SALE OF THE PUBLIC CORD BLOOD INVENTORY FROM AND AFTER CLOSING OF THE ACQUISITION OF SUBSTANTIALLY ALL OF CORD:USES ASSETS. ABOUT CRYO-CELL INTERNATIONAL, INC. FOUNDED IN 1989, CRYO-CELL INTERNATIONAL, INC. IS THE WORLDS FIRST PRIVATE CORD BLOOD BANK. MORE THAN 500,0

CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2023 FINANCIAL RESULTS

OLDSMAR, FLA., OCT. 15, 2021 (GLOBE NEWSWIRE) -- CRYO-CELL INTERNATIONAL, INC. (THE NASDAQ STOCK MARKET SYMBOL: CCEL) (THE COMPANY), THE WORLD'S FIRST PRIVATE CORD BLOOD BANK TO SEPARATE AND STORE STEM CELLS IN 1992, ANNOUNCED RESULTS FOR THE FISCAL THIRD QUARTER ENDED AUGUST 31, 2021.

Cryo-Cell International, Inc.

CCEL

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Cryo-Cell International, Inc.

CCEL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CCEL